 |
|
Cytokine Profile in Fatal Human Immunodeficiency Virus–Tuberculosis–Epstein-Barr Virus–Associated Hemophagocytic Syndrome
Chun K. Wong, PhD;
Bonnie C. K. Wong, MRCP;
K. C. Allen Chan, MRCP, FRCPA;
Gavin M. Joynt, FCCP, FHKAM;
Florence Y. H. Y. Yap, MRCP, FHKAM;
Christopher W. K. Lam, PhD, FRCPath(Hon);
Nelson Lee, MRCP, FHKAM;
Shui S. Lee, FRCP, FHKAM;
Clive S. Cockram, MD, FRCP;
Joseph J. Y. Sung, MD, PhD, FRCP;
Paul K. S. Chan, MSc, MD, FRCPath;
Y. M. Dennis Lo, FRCP, FRCPath;
Julian W. Tang, PhD, MRCP, MRCPath
Arch Intern Med. 2007;167(17):1901-1903.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Hemophagocytic syndrome (HPS), characterized by fever, lymphadenopathy, hepatosplenomegaly, and pancytopenia, results from the abnormal function and proliferation of macrophages and their uncontrolled phagocytosis of various reticuloendothelial cell lines. Secondary (or "reactive") HPS is associated with infection, malignancy, or autoimmune diseases, whereas primary HPS has no identifiable cause and may be genetic. Reactive HPS has been described in association with infectious agents, but Epstein-Barr virus (EBV) is the most commonly associated infection, and EBV-associated HPS is almost universally . . . [Full Text of this Article]Report of a Case
Comment
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008
Cohen et al.
Ann Oncol 2009;20:1472-1482.
ABSTRACT
| FULL TEXT
|
